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Aim The aim of the study was to determine the potential for KV1 potassium channel blockers as inhibitors of human
neoinitimal hyperplasia.
Methods
and results
Blood vessels were obtained from patients or mice and studied in culture. Reverse transcriptase–polymerase chain
reaction and immunocytochemistry were used to detect gene expression. Whole-cell patch-clamp, intracellular
calcium measurement, cell migration assays, and organ culture were used to assess channel function. KV1.3 was
unique among the KV1 channels in showing preserved and up-regulated expression when the vascular smooth
muscle cells switched to the proliferating phenotype. There was strong expression in neointimal formations.
Voltage-dependent potassium current in proliferating cells was sensitive to three different blockers of KV1.3 channels.
Calcium entry was also inhibited. All three blockers reduced vascular smooth muscle cell migration and the effects
were non-additive. One of the blockers (margatoxin) was highly potent, suppressing cell migration with an IC50 of
85 pM. Two of the blockers were tested in organ-cultured human vein samples and both inhibited neointimal
hyperplasia.
Conclusion KV1.3 potassium channels are functional in proliferating mouse and human vascular smooth muscle cells and have
positive effects on cell migration. Blockers of the channels may be useful as inhibitors of neointimal hyperplasia
and other unwanted vascular remodelling events.
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1. Introduction
Smooth muscle cells are well known for their contractile phenotype
which determines the calibre of blood vessels; regulating blood pressure
and local tissue perfusion. However, the cells also retain plasticity
throughout the life, enablingmarked transition away from contractile be-
haviour to motility, invasion, and proliferation. Plasticity is important in
vascular development, adaptation, and response to injury.1 One conse-
quence is the phenomenon of neointimal hyperplasia, which is themove-
ment and proliferation of smooth muscle cells into the luminal area of a
blood vessel, generating a new inner structure that can ultimatelyocclude
blood flow.1–4 It is observed in a variety of situations but is particularly
striking for its tendency to cause failure of interventional clinical pro-
cedures that include the placement of stents and bypass grafts.
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Several mechanisms of smooth muscle plasticity have been deter-
mined,1 but knowledge remains incomplete. An important feature is
changes in the types of ion channel as the cells switch from the
contractile to the proliferating phenotype.5 The intracellular calcium
ion (Ca2+) concentration is one of the key parameters controlled by
the ion channels.6,7 The removal of extracellular Ca2+ or addition of
Ca2+ channel blockers inhibits smooth muscle cell proliferation.8–10
Significantly, as the cells switch from the contractile to proliferating
phenotype, there is loss of CaV1.2 (the L-type voltage-dependent
Ca2+ channel a-subunit) but retention or up-regulation of other
types of Ca2+ channels, including the channel components TRPC1,
STIM1, and Orai1.4,11–17 The suppression of TRPC channel function
inhibits vascular smooth muscle cell migration and proliferation,
whereas suppression of STIM1 or Orai1 has preferential inhibitory
effects on cell migration.15,17 Importantly, an anti-TRPC1-blocking
antibody inhibited human neointimal hyperplasia4 and knock-down
of STIM1 inhibited neointimal formation in a rat model.18 A conse-
quence of the change to these other types of Ca2+ channel is that
it is no longer membrane depolarization that is the trigger for Ca2+
entry, as is the situation in contractile cells where the L-type Ca2+
channels predominate; instead, it is hyperpolarization that causes
increased Ca2+ influx by increasing the electrical driving force on
Ca2+ entry through channels that are not gated by depolarization
but are active across a wide range of voltages, which is the case
with channels generated by TRPC, STIM1, or Orai1 proteins. There-
fore, as in immune cells, ion channels that cause hyperpolarization
become key players.19 Potassium ion (K+) channels are primary can-
didates for mediating the effect.
As with Ca2+ channels, there are changes in K+ channel type as
vascular smooth muscle cells switch from the contractile to prolifer-
ating phenotype.5 As first described by Neylon et al.,20 there is a tran-
sition from the large conductance KCa1.1 (BKCa) channel to the
intermediate conductance Ca2+-activated K+ channel KCa3.1 (IKCa).
It is thought that a reason for the change is that KCa3.1 is more
active at negative membrane potentials, enabling it to confer the
hyperpolarization necessary to drive Ca2+ entry. As predicted, inhibi-
tors of KCa3.1 suppress vascular smooth muscle cell proliferation, ste-
nosis following injury, and neointimal hyperplasia.20–25 Intriguingly,
KCa3.1 is also used by activated lymphocytes to drive Ca
2+
entry.19,26 In some situations, immune cells of this type also use one
more K+ channel for driving Ca2+ entry, a member of the KV1
family called KV1.3.
19,27,28 In this study, we investigated the relevance
of KV1 channels to the proliferating vascular smooth muscle cell and
human neointimal hyperplasia.
2. Methods
2.1 Tissues: cell and organ culture
For murine experiments, 8-week male C57/BL6 mice were killed by CO2
asphyxiation and cervical dislocation in accordance with the Code of Prac-
tice, UK Animals (Scientific Procedures) Act 1986. The thoracic aorta was
removed and placed in ice-cold Hanks’ solution. Endothelium was
removed by brief luminal perfusion with 0.1% (v/v) Triton X-100 in water
and the adventitia was removed by fine dissection.29 Smooth muscle cells
were enzymatically isolated29 and studied immediately or after 14 days of
culture (without passage) when cells were clearly proliferating and non-
contractile. Freshly isolated mouse cells contracted strongly in response to
extracellular ATP, whereas cells in culture showed no contraction or
change in shape. Freshly discarded human saphenous veins were obtained
anonymously andwith informed consent fromadult patients undergoing cor-
onary artery bypass graft surgery and with ethical approval from Leeds
Teaching Hospitals Local Research Ethics Committee. Smooth muscle cells
were grown in DMEM supplemented with 10% FCS, penicillin/streptomycin,
and L-glutamine at 378C in a 5% CO2 incubator; experiments were per-
formed on cells passaged two to five times. All experiments on the intact
vein involved paired comparisons of at least two adjacent vein segments
from the same patient (one in control conditions and the other in the pres-
ence of the blocker). After 14 days of organ culture, neointimal hyperplasia
was thenewcellular layer that developedon the luminal aspect of the internal
elastic lamina andwas quantified using ImageJ software (NIH,USA).22All cells
described as smooth muscle cells stained positively with an antibody to
smooth muscle a-actin and smooth muscle myosin heavy chain (see Sup-
plementary material online, Figure S1).30 The investigation conforms with
the Guide for the Care and Use of Laboratory Animals published by the
US National Institutes of Health (NIH Publication No. 85-23, revised 1996)
and the principles outlined in the Declaration of Helsinki.
2.2 Quantification of channel expression
Methods were similar to those described previously.22,29 Briefly, for
quantification of mRNA abundance, total RNA was first extracted using
Tri-reagent (Sigma) and DNase-treated RNA reverse-transcribed using
enhanced AMV enzyme (Sigma). Real-time polymerase chain reaction
(PCR) was then performed and its specificity verified by melt curve analy-
sis, gel electrophoresis, controls in which reverse transcriptase (RT) was
omitted, and direct sequencing of PCR products (Lark, UK). RNA abun-
dance was normalized to the abundance of 16S mitochondrial rRNA,
which was also analysed by real-time PCR and was not different
between any of the data sets. Sequences of PCR primers are given in Sup-
plementary material online, Table S1. Human cerebral cortex mRNA was
from Ambion. For immunodetection of KV1.3 protein, vessels were fixed
in 10% formalin for ≥24 h and embedded in paraffin wax. Five-
micrometre sections were cut, hot-plated, dried overnight, and stored
at 378C until use. Dewaxing, rehydration, permeabilization, haematoxylin,
and antibody staining using ABC kit (Vector Labs) were according to the
standard protocols. KV1.3 was detected using a monoclonal anti-KV1.3
antibody (clone L23/27; Antibodies Incorp., Davis, USA) and a rabbit
anti-KV1.3 polyclonal antibody.
31
2.3 Ionic current and intracellular Ca21
recordings
Conventional whole-cell recording was performed at 218C using an
Axopatch 200B amplifier and pCLAMP-8 software (Molecular Devices).
Signals were filtered at 1 kHz and sampled at 2 kHz. Patch pipettes had
resistance of 3–5 MV. To the bath solution containing (in mM) NaCl
(135), KCl (5), D-glucose (8), HEPES (10), and MgCl2 (4), 1 mM gadolinium
chloride (GdCl3) was added to suppress background current. The patch
pipette solution contained (in mM): NaCl, 5; KCl, 130; HEPES, 10;
Na2ATP, 3; MgCl2, 2; and EGTA, 5. The pH of solutions was titrated to
pH 7.4 using NaOH. BSA (0.1%) was continuously present to minimize
the non-specific binding of margatoxin. The solvent for correolide C,
psora-4, and Tram-34 was DMSO (≤0.1% v/v). For recording from
HEK 293 cells stably expressing human KCa3.1, the patch pipette solution
contained (in mM): KCl, 144; HEPES, 10; MgCl2, 1.205; CaCl2, 7.625;
EGTA, 10; and the pH was titrated to pH 7.2 using KOH; free Ca2+
and Mg2+ concentrations were 300 nM and 1 mM, respectively. The
bath solution was as indicated above. Intracellular Ca2+ was measured
using fura-2AM (Invitrogen) on a real-time fluorescence 96-well plate
reader (FlexStation, Molecular Devices). The recording medium contained
(mmole/L): NaCl, 130; KCl, 5; D-glucose, 8; HEPES, 10; MgCl2, 1.2; titrated
to pH 7.4 with NaOH. Ca2+ was added to the medium as indicated in the
figure legend.
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2.4 Linear wound and cell migration assays
Smooth muscle cells were cultured on 24- (human) or 96 (mouse)-well
plates to confluency and a 0.3 mm-wide scrape generated across each
well (linear wound). Cells were treated with KV1.3 blockers for 48 h.
Migration assays were performed using a modified Boyden chamber con-
taining polycarbonate inserts with 8 mm pores (BD Biosciences, Oxford,
UK). In brief, 1 × 105 cells were loaded in the upper chamber in DMEM
supplemented with 0.4% FCS. The lower chamber contained 0.4% FCS
supplemented with 10 ng/mL PDGF-BB and 10 ng/mL IL-1a (Invitrogen).
After incubation for 8 h at 378C in a 5% CO2 incubator (with the blocker
or vehicle), cells were scraped from the upper surface, duplicate mem-
branes fixed, and migrated cells stained with haematoxylin and eosin.
Cells were counted in 10 random fields, leading to an average number
of cells per condition per patient.
2.5 Data analysis
Averaged data are expressed as mean+ SEM. Data sets were obtained in
test and control pairs even though single control bars are shown in the
figures. Statistical analysis employed Student’s t-tests with significant
difference indicated by an asterisk (P, 0.05) and no significant difference
by NS. Numbers of experiments are indicated by n (independent exper-
iments on different human or mouse samples, or numbers of individual
recordings for patch-clamp studies) and, in some cases, also N (number
of replicates within an experiment, e.g. wells in a plate). RT–PCR and
tissue staining were repeated independently on samples from three
patients, yielding similar results.
3. Results
3.1 Up-regulated KV1.3 mRNA in
proliferating mouse aorta smooth muscle
cells
A comparison was made of vascular smooth muscle cells in the con-
tractile phenotype (acutely after isolation from the aorta) and the
proliferating phenotype (in primary culture for 14 days). In contrac-
tile cells, RT–PCR detected mRNA species encoding six of the
seven KV1 channels, but in proliferating cells, only mRNA encoding
Figure 1 KV1.3 expression in proliferating vascular smooth muscle cells. (A and B) Mouse cells. (C–E) Human cells and tissue. (A) Gels showing
typical RT–PCR products from RNA of contractile cells (0 day, upper panel) and proliferating cells (14 days, lower panel). In each panel, the 100
bp DNA markers (M) are on the left and the lanes for the encoded channels are ordered from KV1.1 to CaV1.2. See Supplementary material
online, Table S1 for predicted PCR amplicon sizes. (B) Paired mean data for KV1.3 mRNA abundance (n ¼ 9) showing doubling of expression in
14-day cells. (C) Typical RT–PCR products from RNA of the human cerebral cortex (upper gel, positive control) and saphenous vein smooth
muscle cells (lower gel). PCR products for KV1.3 (i) and KV1.4 (ii) mRNAs are highlighted by arrows. Each is a representative of three independent
experiments. (D and E) KV1.3 protein detection in neointima (arrows) of human saphenous vein segments after organ culture. Sections were stained
with monoclonal (D) or polyclonal (E) antibody targeted to KV1.3. The controls were mouse IgG (D) and the absence of primary antibody (E).
Increased intensity in the images indicates increased positive staining. The control image in (E) contains a vein section but it is very faint relative
to the vein stained with anti-KV1.3 antibody. Scale bars are 50 mm; Cntrl, control.
A. Cheong et al.284
KV1.3 was detected (Figure 1A). Quantitative real-time PCR analysis
showed that mRNA encoding KV1.3 increased in abundance in the
proliferating cells (Figure 1B; see Supplementary material online,
Figure S2). Expression of three other ion channels was detected
for comparison (Figure 1A): consistent with previous reports,
expression of mRNAs encoding KCa1.1 and CaV1.2 was lost,
whereas expression of mRNA encoding TRPC1 was retained.4,11–13
Therefore, the experimental system reflected established features of
vascular remodelling and the data suggest that KV1.3 mRNA is an
exception among the KV1 mRNA species, being retained and
up-regulated when vascular smooth muscle cells switch to the prolif-
erating phenotype.
3.2 KV1.3 mRNA and protein in
proliferating human vein smooth muscle
cells
To investigate the relevance to human neointimal hyperplasia, mRNA
was isolated from cultures of human saphenous vein smooth muscle
cells. With regard to the KV1 channels, only mRNA encoding KV1.3
was robustly detected (Figure 1C, i). Small amounts of mRNA encod-
ing KV1.4 may have been present but a specific product could not be
isolated, suggesting exceptionally low expression (Figure 1C, ii). Freshly
isolated cells from the human vein were not investigated because of
concern that the cells would already be partially remodelled in
Figure 2 Effects of KV1.3 blockers on ionic current and intracellular Ca
2+. Data from proliferating human saphenous vein smooth muscle cells
(A–G) or HEK 293 cells stably expressing KCa3.1 (H– J ). All patch-clamp experiments used a holding potential of 260 mV. (A) Example currents
(black circles) evoked by stepping to +40 mV for 0.5 s at 0.1 Hz, showing block by 1 mM correolide compound C (Cor C). (B) Typical Cor C-sensitive
current during a single voltage step. The initial upward spike is residual capacitance current. (C) Typical current–voltage relationship (I–V ) for Cor
C-sensitive current generated used 0.5 s incremental 10 mV depolarizing pulses at 0.1 Hz. The smooth curve is a fitted Boltzmann–Ohm’s Law func-
tion. (D) As for (A) but showing block by 5 nM margatoxin (MgTx). (E) Mean data for the effects of MgTx, Cor C, and Psora-4 (5 nM) on linear
leak-subtracted currents at +40 mV (n ¼ 6, 4, and 4, respectively). Current amplitudes after the blocker had had maximum effect were normalized
to amplitudes before each blocker was applied. Each blocker had its own control (Cntrl). (F) As for (E) except currents were measured at 210 mV;
Cor C data were not obtained because a single step to +40 mV was used in the experiments. (G) Intracellular Ca2+ indicated by the change in fura-2
fluorescence ratio. Cells were pre-treated with thapsigargin (1 mM) to stimulate Ca2+-entry channels and then extracellular Ca2+ (0.2 mM) was added
with or without the presence of 5 nM MgTx (n/N ¼ 4/48). (H and I) Typical currents evoked by stepping to +40 mV showing lack of effect of 5 nM
margatoxin (H) and 1 mM Cor C (I). Block by the KCa3.1 inhibitor Tram-34 (200 nM) confirmed that the majority of current was carried by KCa3.1. (J)
Mean data showing lack of effect of MgTx, Cor C, and 5 nM Psora-4 on KCa3.1 but block by Tram-34 (n ¼ 5, 3, 4, and 14). For each agent, current at
the end of the period of application was normalized to its own control current before the application.
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samples from such patients. To determine the relevance to newly
remodelling smooth muscle cells in situ, we grew neointimal
formations within segments of the human saphenous vein; these
formations are variable in shape and less dense than the original
vessel, containing almost exclusively smooth muscle cells.22 KV1.3
protein was detected using two different anti-KV1.3 antibodies: a
mouse monoclonal antibody (Figure 1D) and a rabbit polyclonal anti-
body (Figure 1E). With either detection antibody, expression of KV1.3
was found to be higher in the neointima compared with the pre-
existing vein (Figure 1D and E).
3.3 Function of KV1.3 protein in K
1
currents and Ca21 entry
To investigate whether there are functional KV1.3 channels, we used
patch-clamp recording to elicit voltage-dependent K+ current in
human vein smooth muscle cells. Three chemically distinct KV1.3
channel blockers were tested for effect: margatoxin, correolide com-
pound C, and psora-4.29,31–36 Depolarizing voltage steps evoked
voltage-dependent K+ current (Figure 2A and B) that had an activation
threshold near 240 mV (Figure 2C), as expected for KV1 channels.
27
The current measured at +40 mV was partially inhibited by correo-
lide compound C, margatoxin, or psora-4 (Figure 2A–E). The percen-
tage inhibition caused by each agent was the same, suggesting a
common site of action (Figure 2E). At negative (physiological) vol-
tages, currents were small and therefore difficult to measure reliably,
but they were nevertheless found to be significantly inhibited at
210 mV (Figure 2F). Further evidence for physiologically relevant
KV1.3 came from intracellular Ca
2+ measurement experiments
where margatoxin significantly suppressed Ca2+ entry, consistent
with the existence of a channel that contributes to the enhancement
of the electrical attraction for the inward movement of the positively
charged Ca2+ ion (Figure 2G). KV1.3 channel blockers showed selectiv-
ity because they had no effects on KCa3.1 channel currents
(Figure 2H– J ). The data suggest that functional KV1.3 channels are
present in proliferating vascular smooth muscle cells.
3.4 Effects of KV1.3 blockers on migration
of mouse and human vascular smooth
muscle cells
To investigate the relevance to cell function, we first used a model of
vascular injury where a linear wound is made in the cell culture,
removing cells from a defined region. Cells responded by regrowing
into the wound (Figure 3A). At a fixed time point, the number of
cells in the wound was counted. Margatoxin or correolide compound
C was tested and found to reduce the number of cells in the wound,
suggesting decreased capacity for response to injury (Figure 3A and B).
Effects on human cells were quantitatively less than for murine cells,
suggesting greater dependence on KV1.3 in the mouse (Figure 3A).
Experiments were also performed on human cells using a Boyden
chamber to explore growth factor-directed cell migration. Again
KV1.3 blockers were inhibitory (Figure 3C). The effects of the blockers
reached a limiting value and were not additive, consistent with all
of the blockers affecting a common mechanism (Figure 3C).
Concentration–response data for margatoxin revealed that the IC50
Figure 3 Actions of KV1.3 blockers on vascular smooth muscle cell migration and response to injury. All data are from human cells except for part
of (B). (A) Typical images of cells after creation of a linear wound (w) delineated by the two dashed lines and making a paired comparison of cells
without (control) and with 1 mM Cor C. Scale bar, 100 mm. (B) As for (A) but mean data for numbers of cells entering the wound in the presence
of the indicated blocker normalized to its own control group (n ¼ 3 for each); for 5 nM MgTx, the control was BSA, and for 1 mM Cor C, it was
DMSO. (C and D) Mean data from the Boyden chamber cell migration assays comparing effects of MgTx (5 nM unless specified differently in D),
Cor C (1 mM), and Psora-4 (5 nM) (n ¼ 4 each). (C) Each blocker group was different from its own control (*) but blocker groups were not signifi-
cantly different from each other. (D) As for (C) but concentration–response data for MgTx with a fitted Hill equation (IC50 85 pM, slope 0.99).
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was 85 pM (Figure 3D), which is similar to the potency previously
reported against KV1.3 channels.
28,32 The data suggest that KV1.3
has a positive role in vascular smooth muscle cell migration and
that margatoxin is a high-potency inhibitor of vascular cell migration.
3.5 Function of KV1.3 in human neointimal
hyperplasia
To determine the relevance to human vascular smooth muscle cells
in situ, we generated neointimal formations in organ cultures of seg-
ments of the saphenous vein, as indicated above. Neointima were
compared in paired vein segments from the same patient, one in
the presence of the vehicle control and the other in the KV1.3
blocker (Figure 4A–D). Treatment with margatoxin inhibited neointi-
mal growth in all four patient samples, averaging 39.87+11.02% inhi-
bition (P, 0.05) (Figure 4E). Correolide compound C was effective in
four out of five patient samples, giving an average inhibition of
60.39+ 16.19% (P, 0.05) (Figure 4F). The data suggest that KV1.3
channels have a positive role in human neointimal hyperplasia.
4. Discussion
The data suggest that KV1.3 is important in proliferating vascular
smooth muscle cells. It is exceptional among the KV1 proteins in
having preserved and up-regulated expression when the cells switch
to their proliferating and migratory phenotype. The proliferating
cells exhibit K+ currents and other functional signals that are sensitive
to inhibition by a range of established blockers of KV1.3 channels
acting in a non-additive manner that is consistent with effects via a
common protein, KV1.3. The blockers exhibit high potency against
human vascular smooth muscle cell migration, in particular marga-
toxin which acts with an IC50 of 85 pM. Results with organ cultures
of saphenous veins suggest the potential for KV1.3 blockers as sup-
pressors of neointimal hyperplasia and other unwanted vascular
smooth muscle cell remodelling events in humans.
Previous studies have established the KV1 family of K
+ channels as
contributors to the control of physiological vascular tone, showing
that they provide negative feedback against depolarizing signals in con-
tractile arterial smooth muscle cells.31,37–39 Although KV1.3 has been
detected in contractile cells, functional importance has mostly been
attributed to other KV1 subunits (especially KV1.2 and KV1.5).
Without excluding contribution of KV1.3 in contractile cells, our
observations suggest that KV1.3 has a more distinctive role in vascular
adaptation, with little or no involvement of other KV1 subunits. The
findings are consistent with a recent report suggesting significance
of KV1.3 in cells of the injured mouse femoral artery.
40 The event
of losing other KV1 subunits may somehow be functionally significant
in phenotypic switching,41 but the mechanism by which this would be
important is unclear and the channel subunits cannot be targets for
pharmacological agents in remodelling because they are not
expressed once the cells switch phenotype. All of the KV1 changes
should be seen within the context of a wider and quite comprehen-
sive alteration in the ion channel expression pattern as smooth
muscle cells switch phenotype.5
The association of KV1.3 with vascular smooth muscle cell adap-
tation is intriguing because this channel is already linked to the pro-
liferation of lymphocytes, oligodendrocytes, and cancer cells.19,42–44
Therefore, the channel may be a fundamental element of proliferating
cells. KCa3.1 is similarly linked to cell proliferation and can co-ordinate
with KV1.3.
19,28 In lymphocytes, KV1.3 dominates over KCa3.1 during
Figure 4 Inhibition of neointimal hyperplasia in human saphenous vein segments. (A–D) Typical images of cross-sections of the vein after organ
culture, showing auto-fluorescence (light grey or white). The panel in (A) labels the structure: L, lumen; NI, neointima; PI, pre-existing intima; M,
media; the scale bar is 100 mm. In all images, edges of L and NI are indicated by dotted lines. (A and B) Paired experiment on vein from one
patient comparing vehicle control (A) and 5 nM MgTx (B). (C and D) Vehicle control compared with 1 mM Cor C. (E and F ) Paired individual data
for veins from four (E) and five patients (F). The area of NI in the presence of MgTx or Cor C is given as a percentage of its area in the corresponding
control.
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chronic inflammation, such that blockers of KV1.3 are suggested as
new therapeutic agents in the treatment of diseases relating to
chronic immune responses, including multiple sclerosis.19,28
Because we detected little or no expression of other KV1 genes,
and KV1 proteins are not thought to mix with other types of KV
protein, our vascular smooth muscle cell data seem to be explained
by KV1.3 acting alone (i.e. as a homotetramer). We found that
KV1.3 mRNA and protein were expressed alone, there was KV1-like
K+ current, and there were effects of three agents at concentrations
that are known to block KV1.3 and do not block KCa3.1.
29,33,36
However, the voltage-dependent K+ current observed, although
similar in some regards to the current generated by over-expressed
KV1.3, showed little or no inactivation, which contrasts with many
reports of the character of heterologously over-expressed KV1.3
channels. We do not know the reason for the difference but speculate
on two possibilities: one possibility is that there is an unknown auxili-
ary subunit in vascular smooth muscle cells that modifies the inacti-
vation properties of KV1.3. Another possibility is that there is tonic
phosphorylation of the channels; Src-dependent phosphorylation
strongly decreases the rate of inactivation of KV1.3
45 and is a
common feature of proliferating vascular smooth muscle cells.
Unfortunately, despite investigating eight different short-interfering
RNA molecules targeted to KV1.3 mRNA and independently
validating our methodology via other targets,15 we were unable to
modify KV1.3 expression and therefore provide evidence using
molecular tools that KV1.3 is involved in the human cells.
The KV1.3 blockers reduced migration of human vascular smooth
muscle cells but it was evident that there was not complete inhibition
(only 40%). This result indicates that there is a component of cell
migration that depends on KV1.3 and a component that does not.
We speculate that this situation arises because the K+ channels
have a modulator function on cell migration, acting by causing hyper-
polarization that enhances Ca2+ entry through non-voltage-gated
Ca2+ channels that arise from proteins such as TRPC1 and STIM1.
According to this hypothesis, the blockade of the KV1.3 K
+ channels
should suppress Ca2+ entry, which is what we observed (Figure 2G).
We previously observed a similar effect with the blockade of
another K+ channel, KCa3.1 blockade.
22 The mechanism by which
the Ca2+ entry facilitates cell migration is unclear and thus requires
investigation.
The data suggest the potential for KV1.3 blockers in therapies against
unwanted vascular remodelling, especially if the remodelling is
accompanied by aggravating chronic inflammatory reactions that
involve KV1.3-expressing immune cells. Although vasoconstrictor
effects of margatoxin have been observed in some arteries,31 elevated
blood pressure has not appeared as a significant concern during in vivo
exploration of KV1.3 blockers for the treatment of multiple scler-
osis,19,28 perhaps, because KV1.5 is commonly expressed in contractile
smooth muscle cells and is resistant to many of the agents that block
KV1.3, or because the roles of the KV1 channels can be taken by
other voltage-gated K+ channels including KV2, KV7, and KCa1.1.
KV1.3 has often been viewed as an immune cell-specific K
+ channel
but is now emerging also as a channel of proliferating vascular smooth
muscle cells and other proliferating cell types. It reflects one of several
similarities in the ion channels of immune cells and vascular smooth
muscle cells, including KCa3.1, TRPC, STIM1, and Orai1 channel sub-
units. The availability of potent KV1.3 channel blockers will facilitate
further research in the area and provide foundations for possible
new cardiovascular therapies.
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